Improved HbA1c and reduced glycaemic variability after 1-year intermittent use of flash glucose monitoring

Wenhui Zhang1, Yu Liu2, Baosheng Sun3, Yanjun Shen4, Ming Li1, Lanbo Peng1, Honggang Duan1, Xudong Su1, Shaoxia Lu3, Xiaoqin Tian5 & Yaqiang Tian5*

Flash glucose monitoring (FGM) was introduced in China in 2016, and it might improve HbA1c measurements and reduce glycaemic variability during T1DM therapy. A total of 146 patients were recruited from October 2018 to September 2019 in Liaocheng. The patients were randomly divided into the FGM group or self-monitoring blood glucose (SMBG) group. Both groups wore the FGM device for multiple 2-week periods, beginning with the 1st, 24th, and 48th weeks for gathering data, while blood samples were also collected for HbA1c measurement. Dietary guidance and insulin dose adjustments were provided to the FGM group patients according to their Ambulatory Glucose Profile (AGP) and to the SMBG group patients according to their SMBG measurements taken 3–4 times daily. All of the participants underwent SMBG measurements on the days when not wearing the FGM device. At the final visit, HbA1c, time in range (TIR), duration of hypoglycaemia and the number of diabetic ketoacidosis (DKA) events were taken as the main endpoints. There were no significant difference in the baseline characteristics of the two groups. At 24 weeks, the HbA1c level of the FGM group was 8.16 ± 1.03%, which was much lower than that of the SMBG group (8.68 ± 1.01%) (p = 0.003). The interquartile range (IQR), mean blood glucose (MBG), and the duration of hypoglycaemia in the FGM group also showed significant declines, compared with the SMBG group (p < 0.05), while the TIR increased in the FGM group [(49.39 ± 17.54)% vs (42.44 ± 15.49)]% (p = 0.012). At 48 weeks, the differences were more pronounced (p < 0.01). There were no observed changes in the number of episodes of DKA by the end of the study [(0.25 ± 0.50) vs (0.28 ± 0.51), p = 0.75]. Intermittent use of FGM by T1DM patients can improve their HbA1c and glycaemic control without increasing the hypoglycaemic exposure in insulin-treated individuals with type 1 diabetes in an developing country.

Type 1 diabetes mellitus (T1DM) is a challenging chronic autoimmune condition resulting in a complete cessation of insulin production. Every year there are an estimated 13,000 new T1DM patients diagnosed in China. Most of them are adults treated with multiple daily injections (MDI) of insulin1,2. There are some unique clinical and demographic characteristics among Chinese type 1 diabetes patients, such as poor blood glucose control, extremely low blood glucose monitoring frequency, irregular insulin treatment, frequent acute and chronic complications, a late onset and a lean body habitus3. It is necessary to achieve favourable glucose levels for T1DM patients to prevent diabetes-related complications, including severe hypoglycaemia, life-threatening diabetic ketoacidosis (DKA), macrovascular complications (such as peripheral arterial disease, coronary heart disease and cerebrovascular disease) and microvascular complications (such as retinopathy, nephropathy and neuropathy)4.

As the basis of modern T1DM treatment, blood glucose monitoring has played an important role for many years. In 1978, self-monitoring blood glucose (SMBG) was first applied in clinical therapy5. The close relationship between SMBG frequency and improved diabetes control has been confirmed by several studies6. However, there are many problems with SMBG, including stress, cost, pain and the required technical skills, which have led to the development of retrospective continuous glucose monitoring (CGM) and real-time continuous glucose monitoring (ReCGM). Intermittent use of FGM by T1DM patients can improve their HbA1c and glycaemic control without increasing the hypoglycaemic exposure in insulin-treated individuals with type 1 diabetes in a developing country.

1Department of Endocrinology, Liaocheng People’s Hospital, Liaocheng 252000, China. 2Cadre Health Care Department, Liaocheng People’s Hospital, Liaocheng 252000, China. 3Department of Endocrinology, Liaocheng Veterans Hospital, Liaocheng 252000, China. 4Department of Pulmonary and Critical Care Medicine, Liaocheng People’s Hospital, Liaocheng 252000, China. 5Department of Endocrinology, Liaocheng Central Hospital, Liaocheng 252000, China. *email: tyq13346255990@163.com
monitoring (rt-CGM)\(^7\). CGM can provide information that SMBG cannot obtain, such as a real-time display of glucose levels and glucose change rates and the ability to characterize blood glucose variability\(^8\). Randomized controlled trials have found that CGM combined with subcutaneous insulin infusion (CSII) or multiple daily injections (MDIs) could decrease haemoglobin A1c (HbA1c) levels and reduce hypoglycaemia\(^9\)–\(^12\). In recent decades, remarkable progress has been made in the management of T1DM, partly due to CGM and rt-CGM technology\(^6\),\(^13\). Although the accuracy and usability of rt-CGM have been gradually improved, this technology has not been widely adopted thus far because of its cost and inconvenience\(^7\),\(^8\).

In 2014, a new continuous glucose monitoring system—flash glucose monitoring (FGM) was introduced to the European Union, and then it was available in China in 2016\(^14\). There are some major differences between FGM and other real-time CGM systems. FGM can provide an ambulatory glucose profile (AGP) for 14 days without any need for blood calibration, which has attracted the attention of clinicians and people with diabetes.

In this study, we divide the patients into the FGM group or the SMBG group and carry out a 50-week single-site randomized controlled trial to compare the differences of HbA1c, TIR, duration of hypoglycaemia and the number of diabetic ketoacidosis events between the two groups. Our overall goal is to investigate whether the use of FGM could be an effective method for achieving improvement of HbA1c and reducing glycaemic variability during T1DM maintenance.

**Methods**

**Study designs and aims.** We carried out a 50-week single-site randomized controlled trial to evaluate the effect of FGM on blood glucose control and variability in T1DM patients with MDI therapy (Fig. 1).

**Sample size.** The estimation of the sample size was based on the estimated incidence of T1DM in China and the results of STAR3 trial\(^2\),\(^15\). A decrease in HbA1c by 0.3% is generally considered a clinically significant decrease to reduce diabetic complications. With a power of 90% at \(P=0.05\) (two-sided), 72 patients in each group are necessary to detect a 0.3% difference in HbA1c between the two groups. Therefore, this study needed 160 patients, who were selected from Liaocheng People’s Hospital, Liaocheng Veterans Hospital and Liaocheng Central Hospital, assuming a dropout rate of 10%.

**Population.** We are trying to establish a T1DM management model in underdeveloped areas. Our hospital serves a catchment area of approximately 10 million people, and our group has been devoted to the registration and management of baseline data for T1DM patients in the Liaocheng area over the past six years. We have determined the prevalence of T1DM in Liaocheng in a previous study, which is consistent with that in Guangdong Province\(^3\),\(^16\). In this study, all of the participants were recruited from our management system, and had received regular and systemic diabetes education.

The inclusion criteria were as follows: (1) age \(\geq 4\) years old; (2) HbA1c \(\geq 7\%\); (3) requiring multiple daily injections (MDIs); and (4) a diagnosis of T1DM for at least 3 months.

The exclusion criteria were as follows: (1) patients with severe complications; (2) pregnancy; and (3) application of FGM and/or CSII in the previous 3 months.

This study has been registered in Chinese clinical trials as ChiCTR-INR-16009665(10/27/2016). In addition, the clinical research program was approved by the Ethics Committee of Liaocheng People’s Hospital. Written and verbal informed consent were obtained from all participants, including those of children under 16, which were obtained from their parent. All experiments were performed in accordance with relevant guidelines and regulations.
Study procedures. Data collection. We collected information on patient age, diabetes course, insulin dosage, and calculated the BMI of the participants. After the HbA1c analysis was performed, all of them wore a FGM for 2 weeks. Data including glucose fluctuations, time in range, mean glucose, and hypoglycaemia time were downloaded and calculated as the baseline during the 1st week without any intervention. Then, the patients were randomly divided into the FGM group or the SMBG group at a ratio of 1:1 by table of random number.

Procedures. Both groups wore the FGM for multiple 2-week periods, beginning with the 1st, 24th, and 48th weeks for gathering data, while blood samples were collected for HbA1c measurement. We gathered baseline data in the 1st week. When the participant scanned the sensor with the reader, he could get current sensor glucose level, a glucose trend arrow, and glucose readings for the previous 8 h. While putting the reader close to the sensor for a few seconds, the participant could get the 14-day glucose profile. In the 2nd week, the FGM group received directions on the best use of FGM, including meanings of the trend arrows and glucose profiles for treatment adjustment, and how to deal with hyperglycaemia and hypoglycaemia. Patients of FGM group were required to perform at least 7 scans per day (before and after meals and before bedtime). At the same time, the SMBG group underwent 3–4 blood glucose measurements daily, including an assessment of FPG and post-meal measurements. Dietary guidance and insulin dose adjustments were made for the FGM group patients according to their Ambulatory Glucose Profile, and for the SMBG group patients according to their SMBG measurements taken 3–4 times daily. From 3 to 23 weeks, the SMBG measurements (3–4 times a day) continued, and routine care from our management system was received by both groups. Both groups wore the FGM device again at 24 to 25 weeks, receiving the same interventions as before while gathering data, and blood samples were collected for HbA1c measurement. Then, from 26 to 47 weeks, all of the participants underwent SMBG measurements and interventions on the days when not wearing the FGM device.

Outcomes. The follow-up phase began at 48 weeks. All of the participants were required to wear the FGM for 14 days again. The data were downloaded and blood samples were collected for HbA1c measurement at the final visit. HbA1c, TIR, duration of hypoglycaemia and the number of diabetic ketoacidosis events were taken as the main endpoints.

Statistical analysis. SPSS statistical software version 17.0 was used to perform the statistical analyses. Normally distributed continuous data are presented as the mean ± SD, and skewed continuous data are summarized as medians. For categorical data, we used numbers and proportions for analysis. All of the data were tested at the 5% significance level. A t-test was applied to analyze normally distributed data and the Wilcoxon signed rank test was used to analyze skewed continuous data. In addition, the chi-squared test was used to assess differences in proportions.

Results
Clinical characteristics. A total of 160 patients were recruited from October 2018 to September 2019 in Liaocheng, Shandong Province. Because of refusal to participate in the study, 146 subjects (64 men, 82 women) were only analysed at baseline. As presented in Table 1, there was no significant difference in the baseline characteristics of either group, including age, course of disease, body mass index and insulin dosages after randomization (p > 0.05). The baseline blood glucose characteristics (HbA1c, TIR, IQR, MBG and duration of hypoglycaemia) in the first week without intervention described in Table 2 also showed no significant differences.

| Group  | n (M/F) | Age (Years) | DM duration (Years) | BMI (kg/m²) | Insulin dosage (u/(kg.d)) |
|--------|---------|-------------|---------------------|-------------|----------------------------|
| FGM    | 71(34/37)| 36.68 ± 19.71 | 4.0 (2.0, 7.0)    | 19.70 ± 2.01 | 0.68 ± 0.08                |
| SMBG   | 75(30/45)| 35.19 ± 18.91 | 5.0 (2.0, 7.0)    | 19.13 ± 1.66 | 0.69 ± 0.07                |
| p-value| 0.34    | 0.64        | 0.67               | 0.06        | 0.43                       |

Table 1. Baseline characteristics of participants [x ± s, M(QU), n/n]. FGM: Flash glucose monitoring; SMBG: Self-monitoring blood glucose; BMI: body mass index.

| Group  | HbA1C(%) | TIR(%) | IQR(mmol/L) | MBG(mmol/L) | Hypoglycemic duration(min/d) |
|--------|----------|--------|-------------|-------------|-----------------------------|
| FGM    | 9.05 ± 1.43 | 36.49 ± 17.57 | 8.39 ± 2.69  | 11.79 ± 2.20 | 201.96 ± 44.28             |
| SMBG   | 9.07 ± 1.18 | 37.87 ± 15.87 | 8.10 ± 1.94  | 11.81 ± 1.93 | 198.13 ± 35.90             |
| p-value| 0.95     | 0.62   | 0.46        | 0.95        | 0.57                       |

Table 2. Baseline blood glucose characteristics of participants (x ± s). TIR: time in range; IQR: interquartile range; MBG: mean blood glucose; Hypoglycemic duration: the time below 3.9 mmol/l.
Compared with FGM at 24 W, p < 0.05; **: Compared with FGM at 48 W, p < 0.01.

interquartile range; MBG: mean blood glucose; Hypoglycemic duration: the time below 3.9 mmol/l. *

(\(p\[(49.39 \pm 17.54)\% \) vs \(42.44 \pm 15.49\)% (\(p\) < 0.05), while TIR increased in the FGM group

showed a significant decline, compared with the SMBG group (8.68 ± 1.01%) (\(p\) < 0.05) and to 7.39% after 48 weeks (\(p\) < 0.05), resulting in an overall difference in HbA1c over the study period. At the same time, the IQR, MBG, and duration of hypoglycaemia also displayed marked decreases at 24 weeks and 48 weeks (\(p\) < 0.05). The TIR increased from 36.49 to 49.39% at 24 weeks to 62.35% by the end of the study (\(p\) < 0.05).

In addition, there was no observed change in the number of DKAs at the end of the study [(0. 25 ± 0. 50) vs (0. 28 ± 0. 51), \(p\) = 0.75].

With regard to safety, no sensor-related adverse events occurred and the few adverse events such as insertion and shedding problems were similar to the events observed in other studies17,19.

Discussion

T1DM is an endocrine metabolic disease in which pancreatic islet \(\beta\) cells are destroyed by the autoimmune system, and insulin therapy is required. The management of chronic hyperglycaemia, hypoglycaemia and blood glucose variability in T1DM is currently difficult in clinical treatment23. Monitoring glucose levels is essential for achieving target glycaemic control and avoiding hypoglycaemia, especially in patients with T1DM.

As a new technology, flash glucose monitoring (FGM) has recently been rapidly accepted by clinicians to replace CGM/SMBG. In FGM, glucose data could be stored for up to 8 h on a sensor and a handheld reader could be used to obtain them conveniently. Moreover, the FGM sensor is factory-calibrated and can be worn for up to 14 days, which improves the patients' quality of life20.

In this study, we aimed to identify whether using FGM can improve glycaemic control among patients with T1DM in Liaocheng District.

The 2017 "International Consensus of Continuous Glucose Monitoring" emphasized that the "three core indicators" of FGM monitoring are TIR, blood glucose variability, and hypoglycaemia. In 2019, Marion Fokkert collected daily life data from persons with DM using the FGM system and found that after a 1-year follow-up, their HbA1c declined from 64 mmol/mol to 60 mmol/mol. In addition, the patients reported increasingly less severe hypoglycaemia and a more active role in treatment21. The study of Ramzi A Ajjan et al. also found similar results. They reported that FGM can improve HbA1c and treatment satisfaction without increasing hypoglycaemic exposure in insulin-treated type 2 diabetes individuals managed in primary/secondary care centres22. Different from our research, they evaluated the Professional FGM blinded to the patients. What's more, the results of a large randomized clinical trial known as IMPACT demonstrated the clinically significant reduction in HbA1c without increasing hypoglycaemic exposure in patients who were randomized to flash CGM, which is consistent with our findings23. The DIAMOND and GOLD studies also showed the benefit of CGM in people using conventional MDI treatment, with the majority of patients having T1DM18,24.

In our study, HbA1c was 9.05% at baseline, demonstrating the T1DM patients' general poor glycaemic control in Liaocheng, while it decreased after intermittent use of FGM by 48 weeks (from 9.05 to 7.39%, \(p\) < 0.05), similar to the above studies. At the same time, their hypoglycaemic duration did not increase. Instead, it decreased sharply by the end of study, which demonstrated that FGM was able to improve HbA1c while also decreasing hypoglycaemic exposure.

Blood glucose variability, also known as blood glucose fluctuations, is an unstable state in which blood glucose levels change between peaks and troughs. The IQR is considered an appropriate value for expressing blood glucose variability27. IMPACT study demonstrated that there were apparent improvements in time in range and glucose variability in patients who were randomized to flash CGM23. In our research, we also observed obvious improvements in TIR at 48 weeks and a reduced IQR, which meant that patients in the intervention group achieved good glycaemic control and reduced blood glucose variability.

Table 3. Comparison of glycaemic parameters across 48-week study (\(\bar{x}\) ± s). TIR: time in range; IQR: interquartile range; MBG: mean blood glucose; Hypoglycemic duration: the time below 3.9 mmol/L. *: Compared with FGM at 24 W, \(p\) < 0.05; **: Compared with FGM at 48 W, \(p\) < 0.01.
A study by Dunn et al. discovered that in real-world conditions, flash glucose monitoring with higher rates of scanning was linked to improved glycaemic markers, including increased time in range and reduced estimated HbA1c from 8.0 to 6.7%[25]. Research by Mingqun Deng also showed that the FGM-derived TIR could be helpful in the glucose management of Chinese adult T1DM patients, while glucose variability should also be taken into consideration in interpreting the relationship between TIR and HbA1c[26]. Our study obtained similar results: after intermittent FGM intervention, the TIR value increased from 36.49 to 62.35% at 48 weeks, and the HbA1c declined to 7.39%.

Many studies have shown that estimating glycaemic control from HbA1c alone can be misleading. Study of Beck et al. highlighted the discrepancy between average glucose and HbA1c on individual level[27]. A flash glucose monitoring system can provide real-time interstitial glucose levels and trends of glucose levels. Moreover, it has the advantage of being precalibrated, so the user does not have to perform any CBG[28]. Beyond that, the users could acquire a patient’s CGM glucose profile, which has considerable value for optimizing diabetes management.

Previous studies have all focused on the influence of the continuous application of FGM for T1DM patients. In China, this is the first study to discuss the effects of 1-year intermittent use of FGM in T1DM patients, which may be a useful strategy for follow-up studies and the application of FGM for diabetes prevention and blood glucose management.

This study has a number of limitations that should be noted. First, the participants could not be blinded to the intervention, which may affect the results. Second, the intermittent intervention could underestimate the potential benefit of FGM. Third, as some of the data including DM duration and insulin dosage were patient-reported, recall bias may be present. Finally, the current population was selected from patients in Liaocheng District, which may introduce selection bias.

**Conclusion**

In summary, intermittent use of FGM in T1DM patients can improve HbA1c and glycaemic control without increasing hypoglycaemic exposure in insulin-treated type 1 diabetes individuals in an developing country.

**Received:** 2 August 2021; **Accepted:** 2 December 2021

**Published online:** 14 December 2021

**References**

1. Miller, K. M. et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and haemoglobin A1c levels in T1D exchange clinic registry participants. *Diabetes Care* **36**(7), 2009–2014 (2013).

2. Weng, J. et al. Incidence of type 1 diabetes in China, 2010–13: Population based study. *BMJ (Clinical research ed)* **360,** j5295 (2018).

3. Li, J., et al. Guangdong T1DM translational medicine study (1): Clinical characteristics of 3159 type 1 diabetic patients.

4. Diagnosis and classification of diabetes mellitus. *Diabetes care.* 33 Suppl 1: S62–S9 (2010)

5. Walford, S., Gale, E. A., Allison, S. P. & Tattersall, R. B. Self-monitoring of blood-glucose: Improvement of diabetic control. *Lancet (London, England)* **1**(8067), 732–735 (1978).

6. Lawson, M. L. et al. The JDRF CCTN CGM TIME Trial: Timing of Initiation of continuous glucose Monitoring in Established paediatric type 1 diabetes: Study protocol, recruitment and baseline characteristics. *BMJ Paediatrics* **14, 183** (2014).

7. Rodbard, D. Continuous glucose monitoring: A review of successes, challenges, and opportunities. *Diabetes Technol. Ther.* **18**(Suppl 2), S3–S13 (2016).

8. Blevins, T. C. et al. Statement by the American association of clinical endocrinologists consensus panel on continuous glucose monitoring. *Endocr. Pract.* **16**(5), 730–745 (2010).

9. Hirsch, I. B. et al. Clinical application of emerging sensor technologies in diabetes management: Consensus guidelines for continuous glucose monitoring (CGM). *Diabetes Technol. Ther.* **10**(4), 232–244 (2008) (quiz 45–6).

10. Tamborlane, W. V. et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. *N. Engl. J. Med.* **359**(14), 1464–1476 (2008).

11. Vigersky, R. A. The benefits, limitations, and cost-effectiveness of advanced technologies in the management of patients with diabetes mellitus. *J. Diabetes Sci. Technol.* **9**(2), 320–330 (2015).

12. Lind, M. et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: The GOLD randomized clinical trial. *JAMA* **317**(4), 379–387 (2017).

13. Battelino, T. et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. *Diabetes Care* **34**(4), 795–800 (2011).

14. Danne, T. et al. International consensus on use of continuous glucose monitoring. *Diabetes Care* **40,** 1631–1640 (2017).

15. Slover, R. B. et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. *Pediatric Diabetes* **13**(1), 6–12 (2011).

16. Shen, Y. et al. Application of real-time continuous glucose monitoring in outpatient management system for type 1 diabetes mellitus. *Chin. J. Endocrinol. Metab.* **33**(5), 367–371 (2017).

17. Shen, Y. et al. Flash glucose monitoring system can reduce glucose volatility in patients with type 1 diabetes mellitus. *Chin. J. Diabetes* **28**(11), 838–841 (2020).

18. Beck, R. W. et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections. A randomized trial. *Ann. Intern. Med.* **167,** 365–374 (2017).

19. Liu, W. et al. Clinical factors associated with glycemic variability analyzed by flash glucose monitoring in type 1 diabetes mellitus. *Chin. J. Diabetes* **28**(4), 265–271 (2020).

20. Evans, M. Current methods of assessing blood glucose control in diabetes. *Br. J. Diabetes* **16**(Suppl 1), 7–9 (2016).

21. Fokkert, M. et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). *BMJ Open Diab. Res. Care* **7,** e000809 (2019).

22. Aijan, R. A., Jackson, N. & Thomson, S. A. Reduction in HBA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial. *Diabetes Vasc. Dis. Res.* **16**(4), 385–395 (2019).

23. Bolinder, J. et al. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: A multicentre, non-masked, randomised controlled trial. *Lancet* **388,** 2254–2263 (2016).

24. Beck, R. W. et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. *JAMA* **317,** 371–378 (2017).
25. Dunn, T. C., Xu, Y., Hayter, G. & Ajjan, R. A. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. Diabetes Res. Clin. Pract. 137, 37–46 (2018).

26. Deng M., et al. Relationship between time in range derived from flash glucose monitoring system and HbA1c. Medical Journal of Peking Union Medical College Hospital. ISSN1674-9081, CN11-5882/R.

27. Beck, R. W. et al. The fallacy of average: How using HbA1c alone to assess glycemic control can be misleading. Diabetes Care 40, 994–999 (2017).

28. Slattery, D. & Choudhary, P. Clinical use of continuous glucose monitoring in adults with type 1 diabetes. Diabetes Technol. Ther. 19, S55–S61 (2017).

Acknowledgements
This study was supported by the Shandong Medical and Health Science and Technology Project (2015WS0392).

Author contributions
All authors have contributed significantly in this manuscript. W.Z. drafted the initial manuscript. Y.T. conceptualized and designed the study. Y.L. and B.S. carried out the initial analysis. Y.S. and X.S. reviewed and revised the manuscript. M.L., L.P. and H.D. helped to conduct statistical analysis and data collection. S.L. and X.T. coordinated and supervised data collection at two other sites and critically reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to Y.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021